Augmentation strategies in selective serotonin reuptake inhibitors resistant obsessive-compulsive disorder - A systematic literature review

Therapeutics, Pharmacology and Clinical Toxicology

Volumn 15, Issue 2, 2011, Pages 83-92

  Vasile, D ^a   Vasiliu, O ^b   Mangalagiu, A G ^b   Ojog, Diana Gabriela ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Military Emergency Universitary Hospital Dr Carol Davila Bucharest   (Romania)

Author keywords

Antidepressants; Antipsychotics; Augmentation strategies; Mood stabilizers; Resistant obsessive compulsive disorder

Indexed keywords

EID: 84857410513     PISSN: 15830012     EISSN: 20660170     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: Methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5(2):181-191.
2. Ipser JC, Carey P, Dhansay Y, Fakier N et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD005473.
3. Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessivecompulsive disorder: A multicenter double-blind trial. J Clin Psychiatry. 2006;67(1):15-22.
4. Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008;23(1):49-53.
5. Pampaloni I, Sivakumaran T, Hawley C, et al. Highdose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey. J Psychopharmacol. 2010 Oct;24(10):1439-45.
6. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: A placebo-controlled study. Arch Gen Psychiatry. 1998;55(10):918-924.
7. Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010;12(2):187-97.
8. McDougle CJ, Goodman WK, Leckman JF et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51(4):302-308.
9. Keuneman RJ, Pokos V, Weerasundera R, Castle DJ. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust N Z Psychiatry. 2005 May;39(5):336-43.
10. McDougle C J, Fleischmann R L, Epperson C N, Wayslink S, Leckmann J F, Price L H. Risperidone addition in fluvoxamine refractory obsessive compulsive disorder: three cases. J Clin Psychiat 1995;56: 526-528
11. Saxena S, Wang D, Bystritsky A, Baxter Jr L R. Risperidone augmentation of SRI treatment for refractory obsessivecompulsive disorder. J Clin Psychiat 1996;57: 303-306
12. Stein D J, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive compulsive and related disorders. J Clin Psychiat 1997;58: 119-122
13. Pfanner C, Marazitti D, Dell'Osso L et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000; 15(5):297-301.
14. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiat 2000; 57: 794-801
15. Hollander E, Rossi N B, Sood E, Pallanti S (2003a) Risperidone augmentation in treatment-resistant obsessive compulsive disorder: a double-blind, placebo controlled study. Int J Neuropsychopharmacol 6: 397-401
16. Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessivecompulsive disorder using adjunctive olanzapine: a placebocontrolled trial. J Clin Psychiatry 2004; 65(4):565-568.
17. Shapira NA, Ward HE, Mandoki M et al. A double-blind placebo controlled trial of olanzapine addition in fluoxetinerefractory obsessive-compulsive disorder. Biol Psychiatry 2004; 55(5):553-555.
18. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(7):514-517.
19. Marazziti D, Pfanner C, Dell'Osso B et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol 2005;19(4):392-394.
20. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 2008; 18(5):364-372.
21. Fornaro M, Gabrielli F, Mattei C et al. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Ann Gen Psychiatry 2008; 7:26.
22. Metin O, Yazici K, Tot S, Yazici AE. Amisulpride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003;18(6):463-467.
23. Carey P D, Vythilingum B, Seedat S, Muller J E, van et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiat 2005;24(5):5.
24. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65(8):1040-1048.
25. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment refractory obsessive compulsive disorder: an open label study. J Clin Psychiat 2002;63:700-703
26. Sevincok L, Topuz A. Lack of efficacy of low dose quetiapine addition in refractory obsessive compulsive disorder. J Clin Psychopharmacol 2003;23: 448-450.
27. Bogan A M, Koran L M, Chuong H V, Vapnik T, Bystritsky A. Quetiapine augmentation in obsessive compulsive disorder resistant to serotonin reuptake inhibitors: an open label study. J Clin Psychiat 2005;66: 73-79
28. Savas HA, Yumru M, Ozen ME. Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig 2008; 28(7):439-442
29. Bloch MH, Landeros-Weisenberger A, Kelmendi B et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Evid Based Ment Health 2007; 10(1):24.
30. Matsunaga H, Nagata T, Hayashida K et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009; 70(6):863-868.
31. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotoninergic antidepressants in treatment-resistant obsessive-compulsive disorder: a metaanalysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007; 17(2):79-93.
32. Pallanti S., Quercioli L., Koran L.M. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. The Journal of Clinical Psychiatry 2002; 63(9):796-801.
33. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 1999; 14(2):101-106.
34. Ross S, Fallon BA, Petkova E et al. Long-term follow-up study of patients with refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2008; 20(4):450-457.
35. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996; 32:677-682
36. Marazziti D, Gemignani A, Dell'Osso L. Trazodone augmentation in OCD: a case series report. CNS Spectr 1999; 4:48-49
37. Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, et al. A double-blind, placebo controlled study of trazodone in patients with obsessivecompulsive disorder. J Clin Psychopharmacol 1992;12:156-162
38. Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 2004;38(3):323-325
39. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 1983;80(3):231-235.
40. Dannon PN, Sasson Y, Hirschmann S et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000;10(3):165-169.
41. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13:219-224
42. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessivecompulsive disorder: preliminary findings. Int Clin Psychopharmacol 1996; 11:37-44
43. Koran LM, Mueller K, Maloney A. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessivecompulsive disorder? J Clin Psychopharmacol 1996; 16:253-254
44. Pigott TA, L'Heureux F, Hill JL, Bihari K, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12:11-18A5. 474
45. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150:647-649
46. Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 1997; 7:147-155
47. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a doubleblind cross-over study. Int J Neuropsychopharmacol 1999; 2:193-195
48. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009;29(1):51-55.
49. Van Ameringen M, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessivecompulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006;23(1):1-5.
50. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998; 59:480-481
51. Koran LM, Aboujaoude E, Bullock KD, et al. Doubleblind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005; 66:353-359
52. Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessivecompulsive disorder. J Clin Psychiatry 2003; 64:1025-1030